A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia
This study has been completed.
Information provided by (Responsible Party):
First received: February 22, 2008
Last updated: September 19, 2012
Last verified: September 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||June 2010|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||January 13, 2012|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K, Karan S, Simmons H, Marcus AI, Ptaszynski M, Kantarjian H. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer. 2012 Jul 15;118(14):3556-64. doi: 10.1002/cncr.26664. Epub 2011 Dec 2.